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ABSTRACT
We have developed a novel technique for specific
amplification of rare methylated DNA fragments in
a high background of unmethylated sequences that
avoids the need of bisulphite conversion. The
methylation-dependent restriction enzyme GlaI is
used to selectively cut methylated DNA. Then
targeted fragments are tagged using specially
designed ‘helper’ oligonucleotides that are also
used to maintain selection in subsequent amplifica-
tion cycles in a process called ‘helper-dependent
chain reaction’. The process uses disabled primers
called ‘drivers’ that can only prime on each cycle if
the helpers recognize specific sequences within
the target amplicon. In this way, selection for the
sequence of interest is maintained throughout the
amplification, preventing amplification of unwanted
sequences. Here we show how the method can be
applied to methylated Septin 9, a promising bio-
marker for early diagnosis of colorectal cancer.
The GlaI digestion and subsequent amplification
can all be done in a single tube. A detection sensi-
tivity of 0.1% methylated DNA in a background of
unmethylated DNA was achieved, which was
similar to the well-established Heavy Methyl
method that requires bisulphite-treated DNA.
INTRODUCTION
The fact that hypermethylation of tumour-associated
genes frequently occurs in early stages of cancer develop-
ment can be exploited for development of epigenetic bio-
markers for early diagnosis, monitoring and
prognostication of cancer (1–3). Indeed, the potential of
several such biomarkers for early detection of cancer, for
predicting outcome and response to therapy and ultim-
ately, for improved management of patients and the
disease has been clearly shown in translational and
clinical settings (3). Examples include detection of
hypermethylated (i) glutathione S-transferase (GSTP1)
in urine and serum samples to help distinguish benign
lesions from prostate cancer (4–6), (ii) vimentin 1 (7,8)
in faeces and Septin 9 genes in blood to detect colon
cancer (9) and (iii) multiple genes (including P16) in
sputum to mark early stages of lung cancer (10–13).
Finally, clinical success of O6-methylguanine-DNA
methyltransferase promoter hypermethylation as a
strong prognostic factor for patients with newly diagnosed
glioblastoma and as potent predictor of response to treat-
ment with alkylating agents is a testament to the clinical
feasibility of these concepts (14–19).
There is now much interest in the use of CpG island
hypermethylation as a tool to detect cancer in the easily
accessible body ﬂuids and tissue specimens from cancer
patients (20). The issue with such type of samples,
however, is the difﬁculty of detection of the
tumour-derived DNA as it is generally present in low
quantities (<0.1%) (21) with most of the DNA being
derived from healthy cells. Thus, translational success of
these approaches hinges on use of excellent detection tech-
nology to detect minute amounts of rare methylated target
DNA in the presence of a vast excess of non-target DNA
that can include both related unmethylated and
methylated sequences.
Several PCR-based assays have been developed, the
majority of which depend upon the use of DNA treated
with sodium bisulphite. Bisulphite treatment deaminates
cytosine, but not 5-methyl cytosine, to uracil (22). This
allows the preservation of the methylation information
through PCR which otherwise would not distinguish
between methylated and non-methylated residues.
Methylation-speciﬁc PCR (MSP) is the most widely used
approach and yields excellent analytical sensitivity,
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detecting up to 0.1% of methylated template in an excess
of unmethylated DNA (23). Based on the differences in
the DNA sequences after the bisulphite treatment, the
primers are specially designed to amplify the methylated
template only. The primary issue with this technology is
the potential for false positive due to mispriming or due to
incomplete bisulphite conversion of DNA (24,25). In an
attempt to tackle these issues, heavy methyl and headloop
suppression PCR methods, which also used bisulphite-
treated DNA as the template, but maintain selection
against unmethylated sequences during each PCR cycle,
were developed. Yielding comparable sensitivity to MSP,
the ‘heavy methyl’ method minimizes the frequency of
false positives through use of oligonucleotide blockers
that block ampliﬁcation of unmethylated DNA (26). In
the case of headloop suppression PCR, primers are
designed to speciﬁcally suppress ampliﬁcation of the
unmethylated sequence (27).
A particular example demonstrating the clinical feasi-
bility of such methods is the application of the heavy
methyl PCR method to detect methylated Septin 9 for
early diagnosis of colorectal cancer (CRC). Detection of
methylation in the Septin 9 promoter region was found to
effectively discriminate CRC from normal specimens (28).
The ability to detect circulating methylated Septin 9 DNA
in plasma has led to the development of a minimally
invasive blood test for CRC (9,29). As mentioned
earlier, bisulphite-treated DNA is most commonly used
for most detection assays. However, these assays suffer
from the drawbacks of this technology, for example
(i) preparation of bisulphite-treated DNA requires
multiple steps (denaturation with NaOH, incubation
with Na-bisulphite, desulphonation and DNA puriﬁca-
tion) and hence, it is time-consuming; (ii) loss of
material due to DNA degradation (30) and handling
steps and (iii) suboptimal conversion rate based on tech-
nical variability, DNA sequence, quality and sample
source which could sometimes lead to inconsistencies
(31); this might be particularly relevant to clinical
specimens.
As an alternative to bisulphite treatment, restriction
enzyme (RE)-based methods have also been used for
site-speciﬁc detection of DNA methylation (32); based
on the type of RE, these enrich for either methylated or
unmethylated DNA. Methylation-sensitive enzymes (e.g.
HpaII, BstUI or AciI) are generally used and these cut
only if the DNA is unmethylated; the lack of cutting is
then detected by PCR of the methylated sequence using
ﬂanking primers. The main source of error here is the
possibility of high background (false positives) arising
from incomplete cutting of the target sites and the
approach has not found wide acceptance. We have
recently described a RE-based method, end-speciﬁc PCR
(ESPCR), which was used for detection of
hypomethylation of repeated DNA sequences following
digestion with methylation-sensitive enzymes (33).
ESPCR uses specially designed helper or facilitator oligo-
nucleotides to speciﬁcally target the cut fragments and
thus is much less affected by incomplete digestion.
The discovery of methylation-dependent enzymes that
cut at speciﬁc target sequences only if those sequences are
methylated allows this approach to be extended to the
detection of hypermethylation. Based on this premise, in
this proof of principle study and using Septin 9 as an
example, we describe a new methylation detection
method that avoids the use of bisulphite. After digestion
with the methylation-dependent enzyme GlaI (34,35), a
particular methylated Septin 9 fragment is speciﬁcally
ampliﬁed by using a new method called ‘helper-dependent
chain reaction’ or ‘HDCR’. This combines ESPCR (33)
with a unique feature that allows maintenance of the se-
lection for the target sequence throughout ampliﬁcation
and thus results in enhanced speciﬁcity. To our know-
ledge, this is the ﬁrst report of a method that results in
the continuous positive selection for a targeted sequence.
MATERIALS AND METHODS
DNAs and oligonucleotides
K562 DNA, puriﬁed from a subculture of the human
chronic myelogenous leukaemia cell line, was obtained
from Promega. CpGenome Universal Methylated DNA
is fully CpG-methylated human male genomic DNA and
was originally obtained from Chemicon (Temecula, CA,
USA). It is now available from Millipore (http://www
.millipore.com/catalogue/item/s7821). Tumour samples
were obtained from patients undergoing surgery at
Flinders Medical Centre (Adelaide, Australia) with
consent having been obtained prior to surgery—Human
Research Ethics Committee approval RGH 09/04.
Following tissue disruption using the Retsch TissueLyser
(Qiagen), DNA from cancer and matched normal tissue
was isolated using a Wizard Genomic DNA puriﬁcation
Kit (Promega).
Oligonucleotide sequences are shown in Table 1. The
helper oligonucleotides (denoted as ‘helper/s’ from here
on) were purchased from Biosearch Technologies
(Novato, CA, USA) or from GeneWorks (Adelaide,
Australia). Other oligonucleotides were purchased from
GeneWorks or from Sigma-Aldrich (Sydney, Australia).
All oligonucleotides were dissolved in TEX buffer (10mM
Tris–HCl, 0.1mM EDTA, 0.01% Triton X-100).
Heavy methyl PCR assay
Genomic DNAs were bisulphite-converted using the EZ
DNA Methylation-GoldTM kit (Zymo Research). The
Septin 9 heavy methyl assay was done, using Quantitect
PCR mix without ROX (Qiagen) as described by de Vos
2009 (9).
GlaI digestion
GlaI RE was purchased from Sibenzyme (http://www
.sibenzyme.com/info627.php). DNAs pre-cut with GlaI
were prepared by digesting 1 mg in ‘SE Buffer GlaI’
(10mM Tris–HCl, pH 8.5 at 25C; 5mM MgCl2; 10mM
NaCl; 1mM 2-mercaptoethanol) plus 16 units of GlaI in a
total volume of 50 ml for 2 h at 30C followed by 15min at
70C. After adding 5 ml of 50mM EDTA and 145 ml of
TEX, the 5 ng/ml digested DNAs were stored at 20C.
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Helper-dependent chain reaction
HDCR was carried out using a Corbett Rotor-Gene 3000
machine with a 72-tube rotor and 10 ml volumes.
Conditions for hot start PCR were 20mM Tris–HCl
(pH 8.4), 50mM KCl, 7.5mM MgCl2, 0.2mM dNTPs,
oligonucleotides (as listed in Table 1), 1/50 000 dilution
of SYBR Green, 0.01mM dithiothreitol, 0.1% Triton
X-100 and 0.04U/ml Platinum Taq Polymerase. GlaI
was included at 0.04 units/ml when the restriction digest
was carried out in the PCR tube.
Suitable cycling conditions for HDCR for 10 ml volumes
and the Rotor-Gene 3000 using pre-cut DNA samples
were ﬁve cycles (90C 15 s, 55C 20 s, 76C 5 s, 67C 20
s) followed by second stage of up to 85 cycles (90C 15 s—
read HEX channel, 67C 40 s, 76C 5 s, 67C 20 s—read
FAM/SYBR Green channel). For the results shown in
Figure 3B, 50C was used in place of 55C in the ﬁrst
stage. When GlaI digestion was done in the PCR mix,
an initial incubation of 10min at 30C was carried out.
The SYBR Green is included to allow a more complete
analysis of the ampliﬁcation if necessary, for example by
allowing a melt curve analysis to be carried out after the
ampliﬁcation. We have found that the addition of a low
level of Triton X-100 in some situations improves the
SYBR Green signal; possibly by preventing loss of the
hydrophobic SYBR Green to surfaces. The dithiothreitol
appears in our experience to be needed to stabilize some
batches of Platinum Taq Polymerase, especially when high
denaturation temperatures are used. For quantiﬁcation,
all samples were diluted such that 2 ng of each was
assayed with a standard curve ranging from 100 pg to
2 ng of fully methylated CpGenome DNA (mixed with
K562 DNA in which Septin 9 is unmethylated to make
a total amount of 2 ng, where necessary). The standards
were cut by GlaI in the initial incubation of the PCR tubes
at 30C, along with the test samples. The correlation
between the two assays was done by assessment of
Spearman’s rank correlation coefﬁcient (Spearman’s rho)
using the Graph Pad Prism, version 5.
RESULTS
We describe here a new one-step PCR-based HDCR
method that can be used to detect cancer-associated
hypermethylation in clinical samples. To show sensitivity
and speciﬁcity of the assay, we used commercially avail-
able DNAs so that other laboratories will be able to make
direct comparisons with other assays already in use.
The concept and strategy
Overall, three primary steps are involved: (1) genomic
DNA is cut with the methylation-dependent RE GlaI,
(2) the GlaI-cut fragment from the target gene is speciﬁc-
ally tagged with 30-extensions at each cut end and (3)
HDCR is used to speciﬁcally amplify and detect the
tagged molecules that derive only from the methylated
target. In these experiments, the Septin 9 gene that is
hypermethylated in >90% of CRC patients (29) was
targeted.
Generation of a methylation-dependent restriction digest
Genomic DNA is cut with the GlaI RE; GlaI cleaves the
DNA sequence, 50-GCGC-30/30-CGCG-50 if there are two,
three or four 5-methylcytosines (5meC, or ‘M’) (34,35)
(Figure 1A). The efﬁciency of cleavage is variable
(6%–100%) based on the quantity and location of
5meCs, as well as the composition of the enzyme recogni-
tion sequence. Fragments generated will be derived from
DNA that is normally methylated as well as sequences
that are speciﬁcally methylated in cancer cells [e.g.
GlaI-cut Septin 9 gene fragment (Figure 1A)]. The
hypermethylated region in the Septin 9 gene includes
two consensus GlaI target sites that are expected to yield
a fragment of 45 bp after GlaI digestion (Figure 1B
and C).
Tagging of GlaI-cut candidate gene using gene-speciﬁc
‘helper’ oligonucleotide
In this step, the target hypermethylated gene is tagged
using a specially designed oligonucleotide—called a
‘helper’, which can bind but cannot be extended thus pre-
venting any copying of annealed genomic DNA.
Speciﬁcally, the helper contains at its 50-end a non-gene-
speciﬁc tag sequence (TAG) followed by a gene-speciﬁc
sequence and then a blocked 30-end. The 30-end comprises
a stretch of three 20-O-methyl residues adjacent to a
30-nucleotide that is mispaired with the target sequence.
The gene-speciﬁc elements of the helper lead to speciﬁc
hybridization to the target. If the target has been cut by
GlaI, then it becomes tagged by copying of the non-
gene-speciﬁc 50-helper sequences (Figure 1C).
HDCR detects the hypermethylated candidate genes in
GlaI-cut DNA mix
HDCR is designed to increase the speciﬁcity of detection
through use of a specially designed primer—called the
‘driver’ together with the ‘helper’ (Figure 2).
Table 1. Oligonucleotide sequences and ﬁnal concentrations used in Septin 9 GlaI-HDCR assay
Oligo name Role Sequence 50 to 30 Puriﬁcation and source Final conc. (nM)
UDr2H Driver F CCCGTMGMMGTMMMTMuuuMTAMAG HPLC, GeneWorks 400
UDr3H Driver R CGCCTMMMGMMTGMTMuuuMATMGA HPLC, GeneWorks 400
S9m3HF354 Helper F GTCGCCGTCCCTCTTTCTACAGTGcgaCCCGCTGCCCuuuT PCR grade, GeneWorks 25
S9m3HR355 Helper R CTCCCGCCTGCTCTTTCATCGATGuugACCGCGGGGTCCuuuT PCR grade, GeneWorks 25
S9HEXPr Probe HEX- CAC[+C]AG[+C]C[+A]T[+C]AT[+G]TCG BHQ1 HPLC, Sigma 50
F= ‘Forward’, R= ‘Reverse’; 20-O-methyl nucleotides are shown in lower case; 5-methyl cytosines are shown as ‘M’; locked nucleic acid residues are
shown as [+C].
PAGE 3 OF 10 Nucleic Acids Research, 2013, Vol. 41, No. 1 e15
 at SerialsCentralLibrary on July 9, 2013
http://nar.oxfordjournals.org/
D
ow
nloaded from
 
Archived at Flinders University: dspace.flinders.edu.au
The driver is complementary to the extended TAG
sequence and acts as a primer to copy the target GlaI
fragment of the Septin 9 sequence and extension of the
target strand occurs (Figure 2, Step 1). However, in the
second strand synthesis, the block in the driver causes pre-
mature termination and prevents the regeneration of the
full binding site for the driver (Figure 2, Step 2). Here the
block to extension is caused by the presence of three 20-O-
methyl uracil bases in the driver that cause the polymerase
to stall.
Ampliﬁcation then becomes dependent upon the
‘helper’ that is required to allow completion of strand syn-
thesis. As in the initial tagging reaction (Figure 1), the
helper anneals to the 30-end of the incomplete strand,
the Septin 9 sequences and ﬁrst six (underlined in Steps
2 and 3 in Figure 2) bases of the TAG sequence. Speciﬁc
binding leads to the copying of the 50 tail of the helper,
thus regenerating the binding site for the driver (Figure 2,
Step 3).
After denaturation, the driver binds to the regenerated
site and the ampliﬁcation cycle continues (Figure 2, Step
4). Because continued speciﬁc binding of the helper to the
target gene sequence is required through the entire ampli-
ﬁcation, very high speciﬁcity is potentially achieved.
As is evident in Figure 2, the sequence of the driver
primer is included within that of the helper
oligonucleotide and both will compete for hybridization
to the tagged Septin 9 strand. In order to improve ampli-
ﬁcation efﬁciency, sequences and reaction conditions need
to be optimized to favour the driver binding and priming.
Here we have increased the driver’s hybridization stability
(i.e. Tm value) through replacement of some of the cyto-
sines by 5MeC in its sequence. This has been shown to
increase stability of binding in other systems (36,37).
Additional bias towards driver binding was obtained
through keeping the concentration of the helper oligo-
nucleotide much lower (40 nM) relative to the driver
(400 nM). Furthermore, after Step 2 (Figure 2) a tempera-
ture spike to 76C is included to facilitate replacement of
the helper with the driver and permit priming of the next
round of ampliﬁcation.
HDCR and detection of hypermethylated Septin 9
The Septin 9 HDCR assay uses a helper/driver combin-
ation at both ends of the 45 bp GlaI Septin 9 fragment
(Table 1). In Figure 2, for clarity, the scheme only shows
reactions from one end. Successful ampliﬁcation of Septin
9 was shown by using a speciﬁc HEX-labelled TaqMan
probe (Table 1). The performance of the assay was ini-
tially demonstrated using CpGenome fully methylated
DNA and K562 DNA as a control in which the Septin 9
gene is unmethylated. To investigate the speciﬁcity of the
Figure 1. Methylation-dependent restriction of genomic DNA and sequence-speciﬁc 30-0 tagging of the cut fragment using the helper. Panel (A): a
schematic describing the methylation-dependent enzyme (GlaI)-based restriction of normal genomic DNA (fragments shown in blue) or that from the
cancer patients (fragments shown in solid black). The fragment representing methylated Septin 9 is shown. Panel (B): the cartoon shows the GlaI
consensus sites and a schematic of Septin 9 digestion using GlaI generating a 45-bp sequence; M: 5-methylcytosine. Panel (C): after GlaI digestion the
cut fragment (example of Septin 9 sequences is shown) is then tagged at its 30-ends using two ‘helpers’ (shown in blue). The helper shown in the upper
part of the ﬁgure contains a non-gene-speciﬁc ‘Tag’ sequence followed by a gene-speciﬁc sequence and a 30-sequence uuuT (u=20-O-methyl uracil
and T is a mismatch with the target) designed to prevent extension. A second helper with similar features is used to tag the other 30-end. The
resulting tags on the 30-ends of both strands of the target Septin 9 target are shown in green.
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reaction, we have studied various mixtures of DNAs
(Figure 3). The sensitivity of HDCR was determined
using samples containing different concentrations of
methylated DNA pre-cut with GlaI (10 pg–10 ng); the
hypermethylation in the Septin 9 gene could be detected
in samples containing only 10 pg of GlaI-cut genomic
DNA (Figure 3A). Because driver hybridization and
priming is reduced due to competition from the helper,
the efﬁciency of ampliﬁcation is signiﬁcantly reduced
compared with standard PCR and detection requires
more cycles. Nevertheless, the requirement for speciﬁc an-
nealing with sequences internal to the Septin 9 fragment
during each cycle leads to a prolonged suppression of
background ampliﬁcation. Speciﬁcity was further
examined in DNA mixtures containing different propor-
tions of GlaI-pre-cut methylated DNA (0 or 0.1% or
100%). HDCR could accurately detect methylated
Septin 9 in samples containing only 0.1% of methylated
DNA (Figure 3B).
HDCR of the hypermethylated Septin 9 gene in clinical
samples
As proof of principle, HDCR was employed to evaluate
the extent of hypermethylated Septin 9 gene in CRC and
matched normal tissues from 25 cancer patients (four
Stage A, nine Stage B, eight Stage C, one Stage D and
four unknown stage). The level of methylation was
determined relative to that of fully methylated
CpGenome DNA. A clear separation of cancer and
normal tissue DNA methylation is evident (Figure 4A).
In considering individual samples, HDCR could detect
hypermethylation in the Septin 9 gene to a level of >5%
in 22/25 (88%) patients (Figure 4B). For all but two of the
subjects, methylation of the Septin 9 gene was
Figure 2. HDCR: quantitative PCR-based selective ampliﬁcation of tagged Septin 9. This ﬁgure describes the main features of HDCR that are
needed to maintain selection for the correct target throughout ampliﬁcation. (1) For the sake of clarity, reactions are shown for one strand only.
Only the lower, 30- to 50-tagged Septin 9 strand from Figure 1 is followed here. (2) A specially designed oligonucleotide, the ‘driver’ (blue sequence),
anneals to the tag (green). The driver contains three 20-O-methyl nucleotides but because they are located 6 nt from the 30-end, they do not prevent
extension and thus the copying of the Septin 9 fragment. (3) In the next round of replication, the new strand formation (copying) stops at the ‘block’
sequence (uuu) in the driver, thus preventing the regeneration of the driver-binding site. (4) After denaturation, an oligonucleotide called the ‘helper’
(shown in red) hybridizes speciﬁcally to the prematurely terminated strand. The hybridizing site consists of 7 nt of tag sequence plus 14 nt of Septin 9.
The helper contains two stretches of 20-O-methyl nucleotides. The stretch close to the helper’s 30-end (lower case, uuu), in combination with a
30-terminal mismatch (T/T), is designed to prevent extension of the helper. The centrally located stretch of 20-O-methyl nucleotides (lower case, cga) is
not essential to the HDCR process. It is designed to reduce background that might occur due to inappropriate priming of non-target fragments on
the helper. Because the helper shares 50-sequences with the driver, copying of the helper’s 50-tail regenerates the driver’s binding site. (5) A 76C
temperature spike is sufﬁcient to remove the helper used here, allowing the driver to access its regenerated binding site. It is important to note that at
this step the driver will be in competition with the helper for binding. Modiﬁcations that decrease helper Tm or that increase driver Tm (such as the
use of 5MeC as used here) and the use of a 10-fold higher concentration of driver aids binding and thus copying of the Septin 9 strand. Selection for
the correct product is maintained throughout the ampliﬁcation because of the continued need of speciﬁc helper binding to the Septin 9 sequence in
every cycle.
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substantially higher in the cancer than matched normal
DNA. In two patients, similar levels of methylation were
seen in matched normal tissue, indicating methylation
variability within normal tissue, methylation in the zone
of pre-neoplastic tissue in which the cancers arose, or that
the normal tissue was contaminated with neoplastic cells.
The Septin 9 HDCR assay was compared with the
heavy methyl assay that is now in clinical use; a signiﬁcant
correlation between the two methods was shown
(Figure 4C) (P=0.0003, Spearman’s rho: 0.6176).
Despite the generally good correlation, in some patients
the methylation level determined by HDCR and heavy
methyl assays differed substantially (Figure 4C and D);
these differences may reﬂect the pattern of CpG site
methylation in the individual patients as selection in the
two assays is based on different CpG sites in the same
region (Supplementary Figure S1).
DISCUSSION
While several novel and promising methylation-based bio-
markers continue to be discovered and characterized, the
efﬁciency of clinical translation of these markers is
compromised due to the lack of adequately sensitive,
speciﬁc and commercially viable assays in simply
acquired and feasible clinical specimens. Based on the
use of GlaI, a methylation-dependent RE and HDCR, a
new and sensitive technique for selective ampliﬁcation,
Figure 3. Detection by HDCR of methylated Septin 9 in genomic DNA mixtures pre-cut with GlaI. In addition to the drivers and the helpers, Septin
9-speciﬁc HEX-labelled Taqman probe was used and ampliﬁcation was detected by measurement of ﬂuorescence at each cycle. Panel (A): ampli-
ﬁcation curves 0–10 ng of fully methylated DNA pre-cut with GlaI. Panel (B): detection of 0.1% GlaI-cut methylated DNA in a background of
GlaI-cut K562 (unmethylated) DNA (10 ng total DNA).
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we have been able to detect the methylated Septin 9 gene
in a 1000-fold excess of unmethylated DNA (Figures 3
and 4). We have compared the sensitivity of detection
on both model DNAs and clinical samples by HDCR to
that obtained using the established heavy methyl assay
(Figure 4C and D), which is currently being developed
for early diagnosis of CRC in blood samples (9,29).
The unique attribute of HDCR is sustained selection of
the target sequence throughout the whole reaction, thus
yielding high levels of analytical sensitivity and speciﬁcity.
This selection occurs at two levels; ﬁrst, only methylated
sequences are cut by the methylation-dependent enzyme
and second, through use of the helpers, the speciﬁc target
sequence is tagged and then the same helpers are used to
maintain selection for the target sequence in each subse-
quent cycle of ampliﬁcation. This results in a very low
background; we could detect methylated Septin 9 in as
low as 10 pg of methylated genomic DNA when present
in a background of 10 ng of unmethylated sample.
Speciﬁc technical features
Once speciﬁc DNA ends have been generated, here by RE
digestion, a combination of two oligonucleotides, the
helper and the driver, at each fragment end is used in an
interdependent manner to drive ampliﬁcation. The helper
binds to gene sequences adjacent to the cut end and acts as
a template allowing only the cut genomic DNA to be
extended (creating a driver-speciﬁc Tag to allow driver
binding). The methylation and site-speciﬁc cutting of
genomic DNA, combined with the hybridization to
gene-speciﬁc sequence of the helper, provide the speciﬁcity
at each end. The ﬁrst important factor is that the helper
should be completely end-blocked so that no extension
can occur. Here we used a combination of three 20-O-
methyl nucleotides (uuu) followed immediately by a
mismatch at the 30-end to prevent any copying of
annealed genomic DNA. Other well-known ways of
blocking extension, such as using a terminal
dideoxynucleotide or a C3-spacer, could be used (38). A
potential source of background is priming on the helper by
other fragments of related sequence. Should this happen
then the product might have sufﬁcient similarity to the
helper that is further ampliﬁed (by being ‘helped’ on all
subsequent cycles). In the example shown here we have
inserted 20-O-methyl residues, shown in lower case, ‘cga’
in the helper sequence (Figures 1 and 2), in order to reduce
this. Furthermore, the 20-O-methyl stretch is positioned
such that only fragments with ends expected to result
from GlaI cleavage will be tagged, thus avoiding ampliﬁ-
cation of molecules that may have been sheared in this
region. Drivers contain a stretch of 20-O-methyl residues
located 6 nt from the 30-end. Such modiﬁcations have been
shown to permit priming while blocking the copying of a
primer (39).
Another important factor concerns the binding of the
driver to its regenerated binding site. At this step, there
is competition from the helper, which is a longer
Figure 4. Detection of methylated Septin 9 in clinical samples by HDCR and GlaI-based single-tube assay. Genomic DNA from patient samples,
cancer biopsies or matched normal tissue was used; HDCR was used to detect methylated Septin 9 after GlaI digestion in the PCR mix. For
comparison, heavy methyl assay was used to detect methylated Septin 9 using bisulphite-treated DNA. Panel (A): a box plot representing percent
methylation in matched normal tissue versus that noted in cancer tissue from 25 CRC patients. Panel (B): the graph shows the same comparison for
individual patients [sample identiﬁcation (ID) numbers, 1–25]. Panel (C): a correlation plot comparing HDCR and heavy methyl-based detection of
percent methylation in cancer, matched normal and normal tissue obtained from 30 subjects. Panel (D): graph shows the comparison between the
detection by two methods for individual subjects. Cancer tissue is represented by sample ID numbers, 1–23 and 26, matched normal tissue corres-
ponding to sample ID numbers, 1, 16, 24 and 25 and normal healthy colorectal tissue is represented by sample ID numbers, 27 and 28. Identical
sample ID numbers in Panels (B) and (D) represent the same patient.
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oligonucleotide and binds to a longer, overlapping site in
the target sequence. This leads to low reaction efﬁciency of
0.3–0.4. Here we have reduced this effect by using 5meC
in the drivers to increase Tm (36,37) and by using low
concentrations of the helpers. Modiﬁed cycling conditions
also help. For example, we used a temperature spike to
76C to remove the copied helpers so that drivers can bind
in the next step (67C) (Figure 2, Step 4). We have further
improved efﬁciency by using inosines in place of some of
the guanosines in the helpers (Supplementary Figures S2
and S3). This modiﬁcation has been shown to reduce the
melting temperatures of oligonucleotides (40). With the
inclusion of inosines, the concentration of the helper can
be increased and HDCR efﬁciency is improved to 0.61;
with 10 ng of input methylated DNA ampliﬁcation is
detected with a Ct of 25. Details of design of helper se-
quences and use of Inosines are provided in the
‘Supplementary Discussion’ section.
The use of HDCR for speciﬁc ampliﬁcation of
methylated sequences is dependent on the availability of
REs that speciﬁcally cut methylated target sequences and
on the location of restriction sites within target regions of
interest. The GlaI enzyme cuts different methylated target
sites with different efﬁciencies, dependent on both primary
sequence and level of methylation (35), so it is important
to evaluate cutting in the context of the speciﬁc sequence
before designing assays. Cutting at speciﬁc sites can be
evaluated experimentally using an in vitro methylated
amplicon covering the target region. While previously
few methylation-dependent REs were known, new
methylation-dependent enzymes with different sequence
speciﬁcities have expanded the range of possibilities for
assay design. In particular, SibEnzyme, the company
that produces GlaI, has been adding to its range of
methylation-dependent REs. Because these enzymes are
relatively new and do not always have straightforward
cutting speciﬁcities, we advise that the most recent infor-
mation on cutting speciﬁcities is obtained from the
company. Methylation-dependent enzymes that belong
to the MspJI family (MspJI, LpnPI and FspE1) have
also recently become commercially available (41). LpnPI
has a recognition sequence of CMNG, and because 5MeC
in mammalian DNA is almost always found in the context
of a CpG dinucleotide, this speciﬁcity effectively becomes
that of a methylated HpaII site, i.e. CMGG, common in
CpG islands. It may be easier to design methylation assays
that use enzymes with such straightforward recognition
sequences. In the Supplementary Data we demonstrate
additional HDCR assays that selectively amplify LpnP1
fragments of genes shown to be methylated in a high
fraction of CRCs, IRF4 (45) and GRASP (unpublished
data). If necessary it should be possible to increase selec-
tion for methylated fragments by including methylation-
sensitive REs such as HhaI or HpaII if sites occur between
the GlaI sites.
Advantageous features of the GlaI-HDCR method
The method described here has several unique features
that overcome hurdles faced by currently available
methods and also signiﬁcantly augment its clinical
relevance.
One signiﬁcant advantage is that it avoids the bisulphite
pre-treatment of DNA, which is costly and technically
time-consuming, prone to variability due to DNA degrad-
ation or inefﬁcient conversion rate (42–44), this is espe-
cially undesirable in the context of clinical setting where
samples might be in limited supply. While the lower per-
cycle efﬁciency means that HDCR takes additional cycles
compared with standard PCR or MSP (up to 150min for
example in Figure 3), this is more than compensated
by the removal of the bisulphite modiﬁcation, normally
4–6 h.
In a standard PCR, speciﬁcity can be lost due to
mispriming events. Even if the original mispriming only
occurred at low efﬁciency, the full primer binding site is
generated in the next round, and priming in subsequent
rounds will therefore proceed at high efﬁciency. This can
lead to the ampliﬁcation of unwanted products or even
primer dimers. This might reduce the ampliﬁcation of
the speciﬁc target to such a degree that false-negative
results are generated. The drivers used in HDCR can
also misprime on non-target molecules. However, a
driver contains a modiﬁcation that prevents its binding
site from being generated. This prevents ampliﬁcation of
non-target molecules and primer dimers. On every cycle
the driver depends upon a helper to regenerate its binding
site. But if the driver has misprimed no help will be given if
the helper is unable to hybridize to the non-target
molecule. Since this selection is maintained throughout
the ampliﬁcation, the overall selection against unwanted
products will be very strong.
Within a genomic GlaI digest we could detect a small
amount of methylated Septin 9 sequence in a mix of cut
methylated sequences from other parts of the genome;
some other GlaI-cut fragments may have sufﬁciently
similar sequences to the target Septin 9 sequence that
they would be ampliﬁed if not for the continuous selection
against them. This sustained speciﬁcity would also address
any additional complexity that could arise from GlaI
cutting at sites other than the consensus sites (35).
We have used HDCR both in a format where DNA is
pre-cut and added to the ampliﬁcation reaction and also in
a one-tube format where all reaction components are
added together and the GlaI digestion is done in the
same tube prior to initiation of ampliﬁcation. Using the
closed tube approach (involving GlaI digestion and sub-
sequent ampliﬁcation in one reaction), we were able to
detect methylated Septin 9 in DNA from 88% of clinical
specimens obtained from the cancer patients (Figure 4).
Use of HDCR in a one-tube format has clear advantages
in a clinical setting. This is dependent on the compatibility
of the restriction digestion conditions and those of the
PCR buffer. GlaI-cutting was only slightly reduced when
carried out in the PCR mix. In contrast to methylation
detection assays that rely on a lack of cutting of
methylated DNA, incomplete cutting by a methylation-
dependent enzyme will not reduce the speciﬁcity of detec-
tion of methylated sequences, but will impact by slightly
reducing sensitivity in proportion to the amount of incom-
plete digestion.
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We anticipate that HDCR will be amenable to multi-
plexing, since a mix of gene-speciﬁc helpers sharing a
common ‘tagging’ sequence could be used in combination
with a single driver at each end. This would be ideal for
use in detection of a panel of biomarkers in clinical
samples.
While described here in the context of detection of
methylation, HDCR has features that can be adapted
for use in a wide range of applications. We envisage that
through appropriate target-speciﬁc design of the driver
and helper oligonucleotides, HDCR could be adapted to
detect other types of methylated genes, hypomethylated
sequences, gene mutations, microsatellite instability and
microRNAs in samples. Because selection for the
targeted sequence can be maintained throughout ampliﬁ-
cation, HDCR should be considered for any applications
in which non-speciﬁc ampliﬁcation is a problem.
SUPPLEMENTARY DATA
Supplementary Data are available at NAR Online:
Supplementary Tables 1–3, Supplementary Figures 1–4.
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